Yun Ju Bae

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Won Seog Kim, Christian Buske, Michinori Ogura et al. · The Lancet Haematology · 2017 · 75 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +8

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Michinori Ogura, Juan‐Manuel Sancho, Seok‐Goo Cho et al. · The Lancet Haematology · 2018 · 63 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +5

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Seung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay et al. · Lara D. Veeken · 2019 · 47 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Jonathan Kay, Janusz Jaworski, Rafał Wojciechowski et al. · Arthritis Research & Therapy · 2021 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

Jin Yong Kim, Oana Săndulescu, Liliana Preoțescu et al. · Open Forum Infectious Diseases · 2022 · 24 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12